Lag 3 inhibitors are shaping up as the next big thing. trials have shown that in combination with PD1 inhibitors they improve efficacy alot. That combination efficacy looks like being the new benchmark. Should we get ahead of the curve and have a pd1/lag3/fto inhibitor vs pd1/lag3 trial in the mix? BP is looking at LAG 3 as the next big thing. If you have trials with LAG 3 in the mix it will help zantrene catch the attention of BP and just seems like a good idea. thoughts? somebody float this with Dr T please.
General Comments / Chat, page-5510
-
- There are more pages in this discussion • 5,554 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |